NASDAQ:IMNN Imunon (IMNN) Stock Price, News & Analysis $0.68 +0.02 (+3.03%) (As of 12/29/2023 ET) Add Compare Share Share Today's Range$0.63▼$0.7250-Day Range$0.66▼$1.1052-Week Range$0.63▼$1.72Volume199,877 shsAverage Volume63,396 shsMarket Capitalization$6.39 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Imunon MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,664.7% Upside$12.00 Price TargetShort InterestHealthy0.15% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.23) to ($1.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.10 out of 5 stars 3.5 Analyst's Opinion Consensus RatingImunon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Imunon has a forecasted upside of 1,664.7% from its current price of $0.68.Amount of Analyst CoverageImunon has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.15% of the float of Imunon has been sold short.Short Interest Ratio / Days to CoverImunon has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Imunon has recently increased by 139.66%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImunon does not currently pay a dividend.Dividend GrowthImunon does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMNN. Previous Next 2.9 News and Social Media Coverage News SentimentImunon has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Imunon this week, compared to 1 article on an average week.Search Interest1 people have searched for IMNN on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Imunon to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Imunon insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.84% of the stock of Imunon is held by insiders.Percentage Held by InstitutionsOnly 4.27% of the stock of Imunon is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Imunon are expected to grow in the coming year, from ($2.23) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Imunon is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Imunon is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImunon has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Imunon Stock (NASDAQ:IMNN)Imunon, Inc., a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma. It also has two platform technologies, such as TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies; and PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.Read More IMNN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMNN Stock News HeadlinesDecember 27, 2023 | americanbankingnews.comImunon (NASDAQ:IMNN) Stock Price Down 3.4%December 11, 2023 | finance.yahoo.comIMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 31, 2023 | Behind the Markets (Ad)FINAL OFFER: $9 for a FULL YEAR of stock picksWe're offering you the chance to subscribe to Behind the Markets for an ENTIRE YEAR for just $9. That's less than a cup of coffee! And what do you get for that $9?November 20, 2023 | finance.yahoo.comImunon, Inc. (NASDAQ:IMNN) Q3 2023 Earnings Call TranscriptNovember 17, 2023 | msn.comIMNN: Promising Interim PFS and OS Data for IMNN-001 in OVATION 2 Trial… - MSNNovember 17, 2023 | finance.yahoo.comIMNN: Promising Interim PFS and OS Data for IMNN-001 in OVATION 2 Trial…November 14, 2023 | finanznachrichten.deImunon, Inc.: IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business UpdateNovember 14, 2023 | tmcnet.comIMUNON's VP of R&D to Present at the Vaccines Summit-2023December 31, 2023 | Behind the Markets (Ad)FINAL OFFER: $9 for a FULL YEAR of stock picksWe're offering you the chance to subscribe to Behind the Markets for an ENTIRE YEAR for just $9. That's less than a cup of coffee! And what do you get for that $9?November 14, 2023 | msn.comImunon GAAP EPS of -$0.37 beats by $0.29November 14, 2023 | benzinga.comImunon: Q3 Earnings InsightsNovember 14, 2023 | finance.yahoo.comIMUNON Reports Third Quarter 2023 Financial Results and Provides a Business UpdateNovember 14, 2023 | finance.yahoo.comIMUNON’s VP of R&D to Present at the Vaccines Summit-2023November 13, 2023 | msn.comImunon Q3 Earnings PreviewNovember 13, 2023 | benzinga.comImunon's Earnings OutlookNovember 7, 2023 | finance.yahoo.comIMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023October 23, 2023 | finance.yahoo.comIMUNON’s Chief Science Officer to Present at the 3rd International Vaccines CongressOctober 19, 2023 | msn.comIMUNON treats first patient in ovarian cancer therapy trialOctober 19, 2023 | finance.yahoo.comIMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United NationsOctober 18, 2023 | finance.yahoo.comIMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian CancerOctober 6, 2023 | finance.yahoo.comIMUNON Appoints Dr. Patrick Ott to its Scientific Advisory BoardSeptember 28, 2023 | benzinga.comImunon Highlights Early Data From Lead Program In Ovarian CancerSeptember 28, 2023 | finance.yahoo.comIMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian CancerSeptember 26, 2023 | finance.yahoo.comIMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and TechnologiesSeptember 18, 2023 | finance.yahoo.comIMNN: R&D Day Highlights Company Pipeline…September 18, 2023 | barrons.comImunon Inc.September 15, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Imunon (IMNN) and Laboratory (LH)See More Headlines Receive IMNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/31/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMNN CUSIPN/A CIK749647 Webwww.imunon.com Phone(609) 896-9100Fax609-896-2200Employees31Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+1,664.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,900,000.00 Net MarginsN/A Pretax Margin-23,541.60% Return on Equity-83.25% Return on Assets-57.05% Debt Debt-to-Equity RatioN/A Current Ratio4.09 Quick Ratio4.09 Sales & Book Value Annual Sales$125,000.00 Price / Sales51.13 Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book0.16Miscellaneous Outstanding Shares9,399,000Free Float9,038,000Market Cap$6.39 million OptionableNot Optionable Beta1.95 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Michael H. Tardugno (Age 72)Executive Chairman Comp: $1.58MDr. Corinne M. Le Goff M.B.A. (Age 58)Pharm.D., CEO, President & Director Comp: $477.73kDr. Khursheed Anwer M.B.A. (Age 63)Ph.D., Executive VP & Chief Scientific Officer Comp: $540.87kMr. Timothy J. Tumminello CPA (Age 65)Chief Accounting Officer & Controller Comp: $108.31kMs. Marianne M. LambertsonVice President of Communications & Investor RelationsDr. Sebastien Hazard M.D.Executive VP & Chief Medical OfficerMore ExecutivesKey CompetitorsAtrecaNASDAQ:BCELCNS PharmaceuticalsNASDAQ:CNSPSoligenixNASDAQ:SNGXTenax TherapeuticsNASDAQ:TENXGalera TherapeuticsNASDAQ:GRTXView All Competitors IMNN Stock Analysis - Frequently Asked Questions Should I buy or sell Imunon stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Imunon in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMNN shares. View IMNN analyst ratings or view top-rated stocks. What is Imunon's stock price target for 2024? 1 Wall Street analysts have issued twelve-month target prices for Imunon's stock. Their IMNN share price targets range from $12.00 to $12.00. On average, they expect the company's share price to reach $12.00 in the next year. This suggests a possible upside of 1,664.7% from the stock's current price. View analysts price targets for IMNN or view top-rated stocks among Wall Street analysts. How have IMNN shares performed in 2023? Imunon's stock was trading at $1.35 on January 1st, 2023. Since then, IMNN shares have decreased by 49.6% and is now trading at $0.68. View the best growth stocks for 2023 here. When is Imunon's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our IMNN earnings forecast. How were Imunon's earnings last quarter? Imunon, Inc. (NASDAQ:IMNN) posted its earnings results on Tuesday, November, 14th. The company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.66) by $0.29. How do I buy shares of Imunon? Shares of IMNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMNN) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.